EASI was created by Prof. Allan Wiik, in collaboration with Pharmacia/Pfizer/Phadia.

Prof. Wiik started  a series of  Nordic "Clinic Meet the Laboratory Meetings"  in 2000 (Edinburgh). Since then, a total of 5 Nordic Autoimmune Meetings have been arranged, the last one in Helsinki May, 2007.

EASI was introduced to European rheumatologists during the EULAR meeting in 2002, and the European Core Group and local EASI teams in various countries were established. Since the 5th International Congress of Autoimmunity in 2006, in Sorrento, the chairman of the EASI Core Group has been Prof. Yehuda Shoenfeld.

The Core group has decided that EASI Congresses will be organized biannually during the International Congress of Autoimmunity (ICA).  EASI Forums, a meeting place for local EASI teams, will be held each year either during the ICA or during the Dresden Symposium on Autoantibodies. Michael Haass from Phadia has been active in organizing the gatherings of EASI teams in different European countries with the support from local Phadia people ín each country.

The  Finnish EASI team was established in 2007, after the last Nordic Meeting, where it was agreed that each Nordic country should have an EASI team of its own. The team members include specialists of rheumatology and diagnostic immunology from rheumatology clinics and diagnostic laboratories.

At the first meeting of the Finnish EASI team in 2007, the following goals were agreed: (click here for details and progress of the projects)

  • Serum bank. 10-20 ml of serum from patients with verified diagnosis of autoimmune disease to be used for validation of new tests.
  • Validation of new tests. Data of evaluation / validation of new tests performed in one laboratory (of the EASI Team) should be available to all other laboratories. Thus we would avoid making duplicate determinations. The results could be available on the website of the Finnish EASI Team, using a password.
  • Recommendation of laboratory tests to be used in diagnostics of autoimmune diseases. The Finnish EASI Team should start a series of publications in Duodecim or Finnish Medical Journal, on diagnostics of autoimmune diseases focusing on the laboratory tests and techniques recommended to be used. Also those inadequate tests still often asked by the customers (and doctors) should be listed, and emphasis should be put on removing those tests from use in Finland. Companies and organizations providing quality assurance programs and accreditation (e.g. Labquality and FINAS) should also be informed.